[go: up one dir, main page]

AR029149A1 - USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO. - Google Patents

USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO.

Info

Publication number
AR029149A1
AR029149A1 ARP990105700A ARP990105700A AR029149A1 AR 029149 A1 AR029149 A1 AR 029149A1 AR P990105700 A ARP990105700 A AR P990105700A AR P990105700 A ARP990105700 A AR P990105700A AR 029149 A1 AR029149 A1 AR 029149A1
Authority
AR
Argentina
Prior art keywords
insulin sensitizer
pharmaceutical composition
plasma concentration
antidiabetic compound
threshold plasma
Prior art date
Application number
ARP990105700A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR029149A1 publication Critical patent/AR029149A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un sensibilizador de insulina que es para la manufactura de un medicamento capaz de proporcionar una concentracion plasmática del sensibilizador de insulina al menos igual a un nivel umbral (la concentracion plasmática umbral) dentro del intervalo de niveles plasmáticos eficaces del sensibilizador de insulina, una composicion farmacéutica y un método para determinar la concentracion plasmática umbral para un compuesto antidiabético.
ARP990105700A 1998-11-12 1999-11-10 USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO. AR029149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
AR029149A1 true AR029149A1 (es) 2003-06-18

Family

ID=10842389

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105700A AR029149A1 (es) 1998-11-12 1999-11-10 USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO.
ARP990105701A AR029317A1 (es) 1998-11-12 1999-11-10 UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990105701A AR029317A1 (es) 1998-11-12 1999-11-10 UN PROCEDIMIENTO PARA PREPARAR UNA COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA.

Country Status (40)

Country Link
EP (2) EP1135128B1 (es)
JP (1) JP2003521455A (es)
KR (2) KR20070048279A (es)
CN (3) CN1235586C (es)
AP (2) AP2005003432A0 (es)
AR (2) AR029149A1 (es)
AT (1) ATE366573T1 (es)
AU (1) AU768303B2 (es)
BG (2) BG110061A (es)
BR (1) BR9915284A (es)
CA (1) CA2350425C (es)
CO (1) CO5150158A1 (es)
CY (1) CY1106892T1 (es)
CZ (1) CZ299801B6 (es)
DE (1) DE69936533T2 (es)
DK (1) DK1135128T3 (es)
DZ (1) DZ2938A1 (es)
EA (2) EA009192B1 (es)
ES (1) ES2289833T3 (es)
GB (1) GB9824893D0 (es)
HK (1) HK1041202B (es)
HR (1) HRP20010344B1 (es)
HU (1) HUP0104262A3 (es)
IL (1) IL143088A0 (es)
MA (1) MA26759A1 (es)
MY (1) MY128347A (es)
NO (1) NO328391B1 (es)
NZ (1) NZ527132A (es)
OA (1) OA12193A (es)
PE (1) PE20001239A1 (es)
PL (1) PL349421A1 (es)
PT (1) PT1135128E (es)
RS (1) RS50130B (es)
SK (1) SK286357B6 (es)
TR (1) TR200101348T2 (es)
TW (1) TWI234456B (es)
UA (1) UA79730C2 (es)
UY (2) UY25797A1 (es)
WO (1) WO2000027341A2 (es)
ZA (1) ZA200103793B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE151634T1 (de) * 1991-08-26 1997-05-15 Upjohn Co Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
RU2195282C2 (ru) * 1993-09-15 2002-12-27 Санкио Компани Лимитед Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm)
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
DZ2938A1 (fr) 2004-03-15
CO5150158A1 (es) 2002-04-29
HRP20010344A2 (en) 2002-06-30
NO20012301L (no) 2001-07-09
AU768303B2 (en) 2003-12-04
DE69936533D1 (de) 2007-08-23
YU37401A (sh) 2005-07-19
NO20012301D0 (no) 2001-05-10
KR20010080440A (ko) 2001-08-22
KR20070048279A (ko) 2007-05-08
CN1771943A (zh) 2006-05-17
DK1135128T3 (da) 2007-11-05
EP1135128A4 (en) 2003-07-16
CN1354661A (zh) 2002-06-19
RS50130B (sr) 2009-03-25
NZ527132A (en) 2005-01-28
EP1135128B1 (en) 2007-07-11
CZ20011656A3 (cs) 2002-06-12
WO2000027341A2 (en) 2000-05-18
ATE366573T1 (de) 2007-08-15
CA2350425C (en) 2009-06-02
CY1106892T1 (el) 2012-01-25
IL143088A0 (en) 2002-11-10
TR200101348T2 (tr) 2002-02-21
SK6422001A3 (en) 2001-12-03
SK286357B6 (sk) 2008-08-05
ZA200103793B (en) 2002-06-05
HRP20010344B1 (en) 2008-02-29
PL349421A1 (en) 2002-07-29
EP1135128A2 (en) 2001-09-26
NO328391B1 (no) 2010-02-08
CN1235586C (zh) 2006-01-11
JP2003521455A (ja) 2003-07-15
UA79730C2 (en) 2007-07-25
HUP0104262A3 (en) 2003-06-30
EA009192B1 (ru) 2007-12-28
MA26759A1 (fr) 2004-12-20
HUP0104262A2 (en) 2002-08-28
PT1135128E (pt) 2007-10-12
AR029317A1 (es) 2003-06-25
MY128347A (en) 2007-01-31
BR9915284A (pt) 2002-02-13
EA200100539A1 (ru) 2001-12-24
BG110061A (bg) 2008-12-30
HK1041202B (en) 2007-10-05
OA12193A (en) 2006-05-09
WO2000027341A3 (en) 2000-09-08
EP1759698A1 (en) 2007-03-07
EA200700968A1 (ru) 2008-06-30
UY25801A1 (es) 2000-08-21
CZ299801B6 (cs) 2008-11-26
PE20001239A1 (es) 2000-12-24
GB9824893D0 (en) 1999-01-06
AP1580A (en) 2006-02-24
BG65577B1 (bg) 2009-01-30
DE69936533T2 (de) 2008-03-13
TWI234456B (en) 2005-06-21
UY25797A1 (es) 2000-12-29
HK1041202A1 (en) 2002-07-05
AU1719600A (en) 2000-05-29
BG105569A (en) 2002-01-31
ES2289833T3 (es) 2008-02-01
CA2350425A1 (en) 2000-05-18
CN101244062A (zh) 2008-08-20
AP2005003432A0 (en) 2005-12-31

Similar Documents

Publication Publication Date Title
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
ES2114487B1 (es) Mezcla estabilizante sinergistica.
EA200100084A1 (ru) Лекарственное средство, обладающее антидепрессивным действием
ES2153836T3 (es) Composicion enmascaradora del sabor de agentes farmaceuticos amargos.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ES2039939T3 (es) Un obturador para protesis de valvula cardiaca, una protesis de valvula cardiaca, con dicho obturador, y un metodo para su fabricacion.
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
PA8501501A1 (es) Material cementoso extruible
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
UY39744A (es) Composición farmacéutica que comprende un agonista de gpr40 y un inhibidor de sglt-2
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
AR023645A1 (es) Metodo para tratar una infeccion por estafilococos
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
AR029149A1 (es) USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO.
ES2087084T3 (es) Composicion de blanqueo.
ES2173871T3 (es) Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía

Legal Events

Date Code Title Description
FB Suspension of granting procedure